Autolus Therapeutics Investor Relations Material

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company engaged in the development of advanced T-cell therapies for the treatment of cancer. The company leverages its proprietary technologies to engineer CAR T-cell therapies aimed at providing life-changing benefits to patients with various cancer types. Some of their key clinical-stage programs focus on therapies for conditions such as adult acute lymphoblastic leukemia and multiple myeloma. Autolus was founded in 2014, following innovative developments in cell programming technology at University College London. The company is headquartered in London, United Kingdom, and its shares are listed on the Nasdaq.